WZWeihe Zhang

Weihe Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weihe Zhang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Immune checkpoint inhibitor‑induced myocarditis with myositis and/or myasthenia gravis overlap syndrome: A case series

    by Qing Sun, Qing Liu, Jiabin Zheng, Yanni Lou, Huijuan Cui, Junyu Ma, Yu Wang, Dantao Peng, Weihe Zhang, Renbin Wang

    Immune checkpoint inhibitors (ICIs) can lead to immune‑related adverse events, including myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS). This syndrome poses notable management challenges and has high mortality rates. Due to limited data, its clinical features and optimal treatment strategies remain poorly understood. The present study aims to clarify these aspects and share clinical management experiences. A total of 6 patients with IM3OS were retrospectively analyzed, collecting demographic, clinical, laboratory, electrophysiological, therapeutic and outcome data. Additionally, the relevant literature was reviewed to contextualize the findings. The 6 patients, all male, with a median age of 70.5 years (range, 63‑83 years), developed symptoms a median of 30.5 days post‑ICI initiation. Common symptoms included fluctuating ptosis, neck weakness, fatigue, myalgia, diplopia, dysphagia, dysarthria and limb weakness. Of the 6 patients, 3 required ventilation support. Elevated creatine kinase (CK) and cardiac troponin I (cTnI) were observed in all patients, with CK and cTnI levels decreasing rapidly post‑treatment. Cardiac troponin T levels remained elevated for 3 months. Myotonic discharge and increased jitter were noted in 2 patients. Treatments included corticosteroids, intravenous immunoglobulin (IVIG), plasmapheresis and rituximab. Pyridostigmine was discontinued in 2 out of 4 patients due to severe cardiac adverse effects. Despite interventions, 2 patients died and 1 was bedridden, with only 3 showing favorable outcomes. In conclusion, IM3OS has a high fatality rate, highlighting the need for prompt intervention in ICI‑treated patients with neuromuscular symptoms. Serum cTnI is a reliable cardiac injury marker, and early treatment with IVIG, plasmapheresis and high‑dose methylprednisolone is recommended. Pyridostigmine should be administered with caution in patients with IM3OS, particularly in the presence of bradyarrhythmic ICI‑related myocarditis. Given the high mortality and disability rates associated with IM3OS, novel biological targeted therapies such as eculizumab and efgartigimod may reduce fatal outcomes.

  • Open Access

    Repulsive guidance molecule-a regulates neutrophil-associated Th17 responses in CNS autoimmunity

    by Weizhe Zhen, Xiaoyi Yang, Jinsong Jiao, Lei Cui, Miaoxin Yu, Qing Sun, Dianjia Gao, Dantao Peng, Ming Jin, Lai Wei, et al.

    Background and aim: Repulsive guidance molecule-A (RGMa) is well-known for its roles in T-cell-mediated neuroinflammation and CNS repair. Innate-adaptive immune interactions, particularly between neutrophils and Th17 cells, are emerging as critical drivers of neuroinflammatory pathology in multiple sclerosis (MS). Whether RGMa regulates these neutrophil-associated Th17 responses remains largely unknown. Elucidating this mechanism may reveal novel therapeutic targets for MS. Methods: Serum levels of RGMa, BMP4, neutrophil elastase (NE), IL-17A, and inflammatory markers were measured in 10 relapsing-remitting MS patients during acute relapse and remission phases, and in 10 healthy controls. In vitro transwell co-cultures using primary human neutrophils and CD3 + T cells were employed to evaluate the effects of RGMa monoclonal antibody (RGMa-mAb) treatment on neutrophil activation, Th17-associated responses, and T-cell migration. In parallel, experimental autoimmune encephalomyelitis (EAE) mice were treated with RGMa-mAb to assess neuroinflammation and BMP4-SMAD-related signaling changes in vivo . Results: Serum RGMa and NE were elevated in acute-phase MS patients versus both remission and healthy controls ( p < 0.05), whereas IL-17A was elevated versus healthy controls ( p < 0.05). Correlation analyses showed that RGMa levels were positively associated with the neutrophil activation marker NE ( r = 0.71), while serum Ly6G6D levels were correlated with IL-17A levels ( r = 0.66), suggesting a potential link between neutrophil-associated inflammatory responses and Th17 activation during active disease. In vitro , RGMa-mAb treatment attenuated PMA-induced neutrophil activation, reduced Th17-associated inflammatory responses, and suppressed T-cell migration in the co-culture system. In EAE mice, RGMa-mAb ameliorated neurological deficits, decreased neutrophil- and Th17-associated inflammatory markers, and modulated BMP4-SMAD signaling. Conclusion: RGMa contributes to neutrophil-associated Th17 inflammatory responses in CNS autoimmunity, potentially in association with BMP4-SMAD signaling. Targeting RGMa may therefore represent a potential therapeutic strategy for MS-associated neuroinflammation that warrants further investigation.

  • Open Access

    Sex-related molecular phenotypes in anxiety-depressive disorders: a machine learning analysis of routine blood biomarkers

    by Weizhe Zhen, Jingjing Chen, Hongjun Zhen, Yanli Zhang, Shiyu Du, Weihe Zhang, Dantao Peng

    Background: Anxiety disorders and depressive disorders are the most prevalent mental disorders worldwide. Their diagnosis has long relied on clinical symptom assessment, and objective blood−based biomarkers remain lacking. Sex is a critical risk factor for these disorders; however, sex−specific divergence in blood biochemical profiles has yet to be systematically characterized. Methods: This retrospective study enrolled 778 patients diagnosed with anxiety−depressive state at China−Japan Friendship Hospital. Demographic data, complete blood count parameters, and blood biochemical parameters were collected. Following missing value processing and multiple imputation, Mann–Whitney U tests were applied to identify sex−differentially expressed biomarkers. A random forest classifier was constructed to evaluate the discriminative capacity of combined multi−marker panels, with model performance comprehensively assessed through receiver operating characteristic curve analysis, SHAP−based explainability analysis, and multi−classifier probability projection. Age−stratified analyses were performed with a threshold of 50 years to explore the potential modifying effect of age on sex differences. Results: Several biomarkers exhibiting significant differences between males and females were identified (FDR < 0.05), among which creatinine, hemoglobin, hematocrit, red blood cell count, and uric acid demonstrated the largest effect sizes. The random forest model achieved an area under the receiver operating characteristic curve of 0.902 on the independent test set. Multi−classifier probability projection following hyperparameter tuning yielded a Silhouette coefficient of 0.464 in the two−dimensional space, with permutational multivariate analysis of variance confirming highly significant centroid differences between groups (p < 0.001). Age−stratified analysis using hemoglobin as an example revealed that levels in males were significantly higher than those in females across both age strata, with the magnitude of the sex difference attenuated in the ≥50−year group compared with the <50−year group. Conclusions: Robust sex−related signals are embedded in routine blood biochemical markers. Although complete separation is difficult to achieve under unsupervised dimensionality reduction, these signals can be efficiently integrated through ensemble learning algorithms. This study provides a molecular phenotypic basis related to sex in patients with anxiety−depressive state and underscores the importance of fully considering sex as a variable in clinical laboratory testing.

  • Open Access

    AQP4-IgG Dynamics and Exploratory Assessment of SERA-3 in Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab

    by Miaoxin Yu, Xiang Li, Lei Cui, Jinsong Jiao, Qing Sun, Yeqiong Zhang, Renbin Wang, Dantao Peng, Yang He, Yujuan Jiao, et al.

    Introduction Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition driven by aquaporin-4 immunoglobulin G (AQP4-IgG). The current treatment paradigm focuses on mitigating clinical relapses and disability accumulation, leaving the underlying serological activity unaddressed. This study evaluated the capacity of satralizumab to achieve a comprehensive remission, as defined by the Serological, Relapse, and Accumulated-disability Remission (SERA-3) target. Methods In this multicenter, real-world cohort study, patients with NMOSD from three tertiary centers in China initiating satralizumab were enrolled. AQP4-IgG levels were measured at baseline, 6, and 12 months. Clinical efficacy [annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS)] and safety were evaluated. Heterogeneity in antibody response was analyzed, and baseline characteristics potentially associated with titer reduction were explored. Results Of the 19 patients who were AQP4-IgG seropositive at baseline, 7 (36.84%) met the strict definition of SERA-3 Complete. Of these, 4 patients achieved seroconversion at month 6 and remained seronegative through month 12, whereas 3 first achieved seroconversion at month 12. An additional 5 (26.32%) showed a reduction in AQP4-IgG titers. Satralizumab treatment was associated with marked clinical benefit. Among 33 patients included in the clinical efficacy analysis, 27 (81.82%) remained relapse-free during follow-up, median ARR decreased from 0.92 (IQR 0.56–1.59) to 0 (IQR 0–0), and EDSS scores remained stable in most patients. Exploratory analyses suggested that patients achieving serological response were older at disease onset (57.42 ± 17.82 versus 42 ± 14.24 years, p = 0.039) and had experienced fewer pre-treatment relapses (median 2 versus 5, p = 0.049). Satralizumab was generally well tolerated, including in older patients. Conclusions Our findings support SERA-3 as a potential treatment framework for NMOSD. Satralizumab was associated with attainment of serological, relapse, and disability remission in a substantial proportion of patients, supporting further prospective evaluation of SERA-3 as a hypothesis-generating outcome framework.

  • Open Access

    A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens

    by Dianjia Gao, Lei Cui, Miaoxin Yu, Qing Sun, Jinsong Jiao, Yu Wang, Dantao Peng, Weihe Zhang

    Neuromyelitis optica spectrum disorder (NMOSD) patients with refractory attacks, despite standard therapy with high-dose intravenous methylprednisolone (IV

  • Open Access

    The diagnosis dilemma of coexistence of neurosarcoidosis and tuberculosis: case reports and literature review

    by Qing Sun, Jinsong Jiao, Renbin Wang, Dongyan Wu, Huaping Dai, Shi Shu, Yunchao Su, Dantao Peng, Weihe Zhang, Xiaohui Duan

    Sarcoidosis is a multisystem disease pathologically characterized by non-caseating epithelioid granulomas. Its neurological form, neurosarcoidosis (NS), can affect the central nervous system (CNS) and/or the peripheral nervous system (PNS), posing a significant diagnostic challenge. The diagnostic dilemma is further complicated by the significant clinicopathological overlap between sarcoidosis and tuberculosis (TB). Although rare, sarcoidosis and TB can coexist. Our case series included three NS patients: two had CNS involvement and one had PNS involvement. Notably, two patients had confirmed active tuberculosis infection and one patient had a latent TB infection. This highlights the diagnostic and therapeutic challenges of these coexisting conditions. Fluorodeoxyglucose positron emission computed tomography (FDG PET) helps detect extraneural sarcoidosis locations and find biopsy sites. Regarding the similarity and potential coexistence of TB and sarcoidosis, thorough screening for TB infection is essential before initiating any therapy for sarcoidosis.


  • Open Access

    Predict disabling severe attacks in neuromyelitis optica spectrum disorders: warning symptoms and innovative machine learning models

    by Weizhe Zhen, Lei Cui, Yeqiong Zhang, Jinsong Jiao, Yujuan Jiao, Renbin Wang, Hongjun Zhen, Weihe Zhang, Dantao Peng

    Severe disabling attacks neuromyelitis optica spectrum disorders (NMOSD) severely affect patients’ quality of daily life and life safety. This retros


  • Open Access

    RGMA gene polymorphisms as predictive biomarkers for early relapse in neuromyelitis optica spectrum disorders

    by Xiaoyi Yang, Lei Cui, Jinsong Jiao, Yeqiong Zhang, Renbin Wang, Dantao Peng, Weihe Zhang

  • Pilot Exploration of RGMa-BMP4 Signaling in Neutrophil Activation in NMOSD: Integrating Clinical and Molecular Insights

    by Weihe Zhang, Lei Cui, Yeqiong Zhang, Yang He, Xiaoxuan Li, Yu Wang, Jinsong Jiao, Dantao Peng, Ming Jin, Cheng Xiao

    Neuromyelitis optica spectrum disorder (NMOSD) is a disabling autoimmune disease. Neutrophil activation plays a crucial role in the neuroinflammatory damage observed during disease exacerbations. This study aims to elucidate the potential role of the repulsive guidance molecule A-bone morphogenetic protein 4 (RGMa-BMP4) signaling pathway in neutrophil activation during NMOSD attacks. We employed transcriptomic sequencing, quantitative PCR, flow cytometry, and Western blot analysis on peripheral blood samples from NMOSD patients in acute and remission phases. Additionally, an NMO rat model was established to investigate in vivo molecular mechanisms, focusing on key signaling molecules, including RGMa, BMP4, and SMADs. Transcriptomic analysis identified five genes associated with NMOSD pathogenesis or neutrophil activation, with RGMA, EGFR, and HLA-DOB showing the most significant differences. RT-qPCR confirmed elevated levels of RGMA, BMP4, and SMADs in the acute phase. Flow cytometry and Western blotting demonstrated an increased nuclear-to-cytoplasmic ratio of SMAD4 protein in neutrophils from acute-phase NMOSD patients. In the NMO rat model, we observed significant upregulation of RGMA, BMP4, and SMAD4 mRNA in brain and spinal cord tissues, along with enhanced nuclear translocation of SMAD4 protein. Furthermore, there was a marked increase in myeloperoxidase (MPO) mRNA expression, a marker of neutrophil activation, in both brain and spinal cord tissues in the model group. Our findings indicate that the RGMa-BMP4 signaling pathway likely plays a key role in neutrophil-mediated neuroinflammation during NMOSD attacks. These results suggest potential therapeutic targets within this pathway, warranting further investigation into their clinical implications.


  • Decreased NETosis-related regulators in neuromyelitis optica spectrum disorders after plasma exchange

    by Weihe Zhang, Lei Cui, Jinsong Jiao, Yeqiong Zhang, Chuanzheng Ma, Dantao Peng, Ming Jin